BioLineRx Ltd.
BLRX
$2.52
-$0.13-4.91%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Net Income | 77.05% | 63.66% | 102.61% | 94.28% | -142.26% |
Total Depreciation and Amortization | 174.96% | 280.09% | 140.40% | 246.33% | 245.99% |
Total Amortization of Deferred Charges | 1,157.63% | -- | -- | -- | -- |
Total Other Non-Cash Items | -317.56% | -129.77% | -152.90% | -197.95% | 347.00% |
Change in Net Operating Assets | -102.79% | -394.01% | -659.92% | -4,045.05% | 1,064.37% |
Cash from Operations | -272.51% | 0.77% | -17.01% | -76.01% | 187.82% |
Capital Expenditure | 137.50% | 100.00% | 59.70% | 0.00% | 71.93% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 154.72% | 148.29% | -177.17% | 150.51% | -620.01% |
Cash from Investing | 154.70% | 148.35% | -177.88% | 151.23% | -628.09% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -1,302.43% | -10.19% | -578.36% | -1,724.49% | -818.09% |
Issuance of Common Stock | -12.77% | -- | -- | -- | 420,000.00% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | -109.45% | -134.81% | 17,920.15% | -1,724.49% | 1,914.53% |
Foreign Exchange rate Adjustments | -15.63% | 212.50% | -10.57% | 152.04% | 484.00% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 146.08% | 66.89% | 250.00% | 214.07% | -37.89% |